STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
ATRS ANTARES PHARMA INCORPORATED StockScouter® Report
2
StockScouter® Score
ANTARES PHARMA INCORPORATED, a small cap growth company in the healthcare sector, is expected to underperform the market over the next six months with slightly higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Moving average analysis for ATRS suggests strong price movement over the medium term. Positive
Concerns
- The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
- The multi-period measure of relative price change and consistency is well below average. Negative
- The enterprise value-to-sales ratio is higher than the average for comparably-sized companies in the StockScouter universe. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that small cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
F
C
D
F